NOVARTIS: FY 2019 guidance increased again on the back of another strong quarter | BUY | CHF106(+24%)
NOVARTIS - BUY | CHF106(+24%)FY 2019 guidance increased again on the back of another strong quarter
Sales up 13% in the third quarter
Margin improvement and strong cash-flow generation
Guidance revised upwards for the third time this year
Fevipiprant misses the FEV1 endpoint in the first two trials
Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.